Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells

被引:15
|
作者
Wang, Kaifang [3 ,4 ]
Cai, Rong [1 ,2 ]
Fei, Shuting [1 ,2 ]
Chen, Xuzheng [2 ]
Feng, Sisi [1 ,2 ]
Zhang, Lulu [1 ,2 ]
Liu, Hui [1 ]
Zhang, Zhiguang [1 ,2 ]
Song, Jun [1 ,2 ,5 ]
Zhou, Ruixiang [1 ,2 ,5 ]
机构
[1] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Peoples R China
[2] Fujian Med Univ, Minist Educ, Key Lab Gastrointestinal Canc, Fuzhou, Peoples R China
[3] Shenzhen Univ, Sch Dent, Med Sch, Shenzhen, Peoples R China
[4] Hong Kong Baptist Univ, Fac Sci, Dept Biol, Hong kong, Peoples R China
[5] Fujian Med Univ, Sch Basic Med Sci, Fuzhou 350122, Fujian, Peoples R China
关键词
Melatonin (MLT); Gastric cancer; Exosomes; Macrophages; Tumor microenvironment; PATHWAY;
D O I
10.1016/j.mce.2023.111917
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Melatonin (MLT) is a hormone with potential anti-tumor properties, but the molecular mechanisms remain unclear. The present study aimed to explore the effect of MLT on exosomes derived from gastric cancer cells, with the goal of gaining insight into its anti-tumor activity. Results from in vitro experiments showed that MLT was able to enhance the anti-tumor activity of macrophages that had been suppressed by exosomes from gastric cancer cells. This effect was achieved through regulation of the levels of PD-L1 in macrophages via modulation of the associated microRNAs in the cancer-derived exosomes. Furthermore, MLT treatment increased the secretion of TNF-alpha and CXCL10 by the macrophages. Besides, MLT treatment of gastric cancer cells led to the production of exosomes that promoted the recruitment of CD8+ T cells to the tumor site, resulting in inhibition of tumor growth. Collectively, these results provide evidence for the modulation of the tumor immune microenvironment by MLT through regulation of exosomes derived from gastric cancer cells, suggesting a potential role for MLT in novel anti-tumor immunotherapies.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Exosomes derived from colorectal cancer cells suppress B-cell mediated anti-tumor immunity
    Zhang, Yukun
    Yu, Yeping
    Gu, Xiaodong
    Li, Zhenyang
    Zhou, Yiming
    Xiang, Jianbin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 148
  • [32] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
    Kevin Durgan
    Mohamed Ali
    Paul Warner
    Yvette E. Latchman
    Cancer Immunology, Immunotherapy, 2011, 60 : 547 - 558
  • [33] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
    Durgan, Kevin
    Ali, Mohamed
    Warner, Paul
    Latchman, Yvette E.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 547 - 558
  • [34] PD-L1 Checkpoint Blockade Using a Single-Chain Variable Fragment Targeting PD-L1 Delivered by Retroviral Replicating Vector Enhances Anti-Tumor Effect in Cancer Models
    Lin, Amy H.
    Yagiz, Kader
    Hofacre, Andrew
    Munday, Anthony W.
    Espinoza, Fernando Lopez
    Mendoza, Daniel
    Burrascano, Cynthia
    Gruber, Harry E.
    Mitchell, Leah A.
    Jolly, Douglas J.
    MOLECULAR THERAPY, 2018, 26 (05) : 54 - 54
  • [35] CANCER STEM CELLS AND PD-L1-EXPRESING EXOSOMES SUPPRESS ANTI-TUMOR EFFECTOR B CELLS
    Xin, Ying
    Qin, You
    Wicha, Max
    Chang, Alfred
    Li, Qiao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1184 - A1184
  • [36] S-allylmercaptocysteine promotes anti-tumor immunity by suppressing PD-L1 expression
    Zhao, Zhongxi
    Wei, Guangwei
    Zhao, Jianxiong
    Sun, Yueyue
    Gao, Peng
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 161
  • [37] BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
    Zhu, Hengrui
    Bengsch, Fee
    Svoronos, Nikolaos
    Rutkowski, Melanie R.
    Bitler, Benjamin G.
    Allegrezza, Michael J.
    Yokoyama, Yuhki
    Kossenkov, Andrew V.
    Bradner, James E.
    Conejo-Garcia, Jose R.
    Zhang, Rugang
    CELL REPORTS, 2016, 16 (11): : 2829 - 2837
  • [38] Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
    Jiang, Yuying
    Yang, Yongbing
    Hu, Yingchao
    Yang, Rui
    Huang, Jiajia
    Liu, Yi
    Wu, Yuqing
    Li, Sheng
    Ma, Chunmei
    Humphries, Fiachra
    Wang, Bingwei
    Wang, Xi
    Hu, Zhibin
    Yang, Shuo
    CELL REPORTS, 2022, 41 (04):
  • [39] KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
    Li, Jinghan
    Shi, Daiwang
    Li, Siyi
    Shi, Xiang
    Liu, Yu
    Zhang, Yi
    Wang, Gebang
    Zhang, Chenlei
    Xia, Tian
    Piao, Hai-long
    Liu, Hong-Xu
    CELL DEATH & DISEASE, 2024, 15 (02)
  • [40] Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer
    Unal, Bilal
    Kuzu, Omer Faruk
    Jin, Yang
    Osorio, Daniel
    Kildal, Wanja
    Pradhan, Manohar
    Kung, Sonia H. Y.
    Oo, Htoo Zarni
    Daugaard, Mads
    Vendelbo, Mikkel
    Patterson, John B.
    Thomsen, Martin Kristian
    Kuijjer, Marieke Lydia
    Saatcioglu, Fahri
    NATURE COMMUNICATIONS, 2024, 15 (01)